Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),
potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase
inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant lung cancer, although …

Importance Non–small cell lung cancer remains the leading cause of cancer death in the
United States. Until the last decade, the 5-year overall survival rate for patients with …

T cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells,
including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell …